Small Molecules
19 December 2019
Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder19 December 2019
PharmaMar has filed New Drug Application for lurbinectedin with the FDA for the treatment of relapsed small cell lung cancer19 December 2019
SPRAVATO (Esketamine) Nasal Spray Approved in Europe for Adults with Treatment-Resistant Major Depressive Disorder18 December 2019
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment18 December 2019
Poxel Announces Positive Results for PXL065 Phase 1b Trial and Provides Program Update17 December 2019
TransThera Biosciences Announces IND Approval from FDA for Clinical Studies of TT-00920 to Treat Chronic Heart Failure17 December 2019
ARMGO® Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies17 December 2019
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Significant Treatment Benefit for People with ALS in the CENTAUR Trial17 December 2019
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer16 December 2019
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder16 December 2019
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide16 December 2019
ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist at 2019 San Antonio Breast Cancer Symposium16 December 2019
Futility Analysis Performed of the Phase II Combination Study with Birinapant and Keytruda® in Colorectal Cancer Patients16 December 2019
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma15 December 2019
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk13 December 2019
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure13 December 2019
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease13 December 2019
Janssen Receives Positive CHMP Opinion for Expanded Use of Erleada® (apalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer13 December 2019
Trevena Presents Phase 1 Data on TRV250 for Acute Migraine at American College of Neuropsychopharmacology 2019 Annual Meeting13 December 2019
Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid Tumors at 2019 SABCSNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports